12/07/2019
Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer
12/07/2019
Bristol-Myers Squibb Announces Liso-Cel Met Primary and Secondary Endpoints in TRANSCEND NHL 001 Study
12/06/2019
Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma
12/06/2019
Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)
菜根譚の標榜人 2019年12月8日 14:28
【戯言】
下記は、ブリストル・マイヤーズスクイブ(BMS社)のホームページの、プレスリリース(投稿済み)ですが、小野薬品の様に惜しみなく?出状しても、NY市場ではBMYのIR(掲載省略)後の12月4日に2%超上げているようですが、東証参加の投資家の反応は今一、残念に尽きます、もっとも小野薬品とは別会社ですが。
BMS社プレスURL⇒ ttps://www.bms.com/media/press-releases.html
12/07/2019
Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer
12/07/2019
Bristol-Myers Squibb Announces Liso-Cel Met Primary and Secondary Endpoints in TRANSCEND NHL 001 Study
12/06/2019
Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma
12/06/2019
Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)